Real-world evidence study on the long-term safety of everolimus in patients with tuberous sclerosis complex: final analysis results

HIGHLIGHTS

• who: Andreas Hahn et al. from the United Kingdom McGill University, Canada have published the research: Real-World Evidence Study on the Long-Term Safety of Everolimus in Patients With Tuberous Sclerosis Complex: Final Analysis Results, in the Journal: (JOURNAL) of 10/08/2017
• what: The aim of the TOSCA PASS was to document the long-term safety and tolerability profile of everolimus prescribed for the licensed indications in patients with TSC residing in the EU (Kingswood et_al, 2014). The primary reasons for discontinuation were registry termination by the sponsor (n=25, 14%), loss to . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.